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Summary
QUESTION UNDER STUDY: In Switzerland, vaccination
against varicella is not recommended in the basic immun-
isation schedule. However, for individuals aged 11–40
years who do not have a reliable varicella history the Swiss
Federal Office of Public Health recommends either (i) a
vaccination or (ii) a serology test and vaccination of those
with a negative result. In the Travel Clinic of the University
of Zurich, the second strategy is followed. In this study
we retrospectively assessed the overall percentage of indi-
viduals with varicella-specific antibodies despite a negat-
ive history and we examined the influence of age, number
of siblings, order of siblings, age difference to siblings and
nationality on varicella seropositivity.
METHODS: Between December 2008 and August 2015,
the sera of 1757 individuals with a negative varicella his-
tory were tested for varicella antibodies.
RESULTS: A total of 1593 individuals (91%) had a posit-
ive result. We found an increasing trend for varicella sero-
positivity with increasing age. Those aged less than 40
years were significantly more often seronegative (9.5%)
than those aged 40 years and above (6.0%, p = 0.049).
Seropositivity was associated with nationality. The per-
centage of seropositives increased with the number of sib-
lings.
CONCLUSIONS: Our results indicate that, despite the sig-
nificant varicella seropositivity differences between those
aged below and above, the age of 40 may not be an ideal
threshold for performing a varicella serology in individuals
with a negative or unknown varicella history. In the age
groups above 40, testing for varicella antibodies may be es-
pecially reasonable in individuals with no or a small num-
ber of siblings and in those of specific nationalities.
Key words: varicella zoster virus infection; chickenpox;
seroprevalence
Introduction
Varicella is the primary infection caused by the highly con-
tagious varicella zoster virus (VZV). Most individuals con-
tract varicella during childhood, when varicella in immun-
ocompetent individuals is usually a self-limited disease and
only rarely leads to complications [1].
According to previous studies conducted in Switzerland
between 1994 and 2005, VZV seroprevalence in adoles-
cents and young adults ranges between 94% and 97%
[1–5]. Although seroprevalences show regional differen-
ces, studies from other Western European countries report
comparable VZV prevalences [6–8]. Seroprevalence has
increased in some tropical countries over recent years, but
it still remains significantly lower than in Europe, and vari-
cella infections in tropical countries tend to occur at later
ages [9, 10]. If varicella infection is contracted in adult-
hood, the risk of complications such as pneumonia, en-
cephalitis or meningitis is higher than in children [11]; in
Switzerland, the frequency of hospitalisations for adults is
16 times higher and mortality is increased 40 times [12].
The prevalence of VZV infection appears to be associated
with the number of siblings a person grew up with [2, 13].
Similarly, in a study conducted in Guinea Bissau, house-
hold size was a critical risk factor for varicella transmission
[10]. However, in Swiss and other European studies,
neither socioeconomic status, living in urban versus rural
areas nor gender predicted the prevalence of VZV antibod-
ies [2, 8].
Vaccination against varicella is recommended as part of
routine childhood vaccination schedules in several coun-
tries, such as the United States and Germany [14, 15]. In
Switzerland, vaccination against varicella during childhood
is not generally recommended and varicella is not a noti-
fiable disease. The Swiss Federal Office of Public Health
recommends the following approach in individuals aged 11
to <40 years who have not contracted varicella naturally in
the past (i.e. who do not have a reliable varicella history),
to either (i) vaccinate or (ii) to perform VZV serology
and vaccinate those with a negative result. The threshold
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of 40 years was chosen on the assumption that almost all
individuals will have contracted varicella by the age of
40 and thus testing for varicella seropositivity is unneces-
sary above this age. The Travel Clinic of the University of
Zurich follows the second strategy.
In the current study, we retrospectively assessed VZV ser-
ology data obtained from all individuals seeking pre-travel
advice at our clinic between December 2008 and August
2015 with a negative or uncertain varicella history who
were tested for VZV antibodies.
The objectives were (i) to evaluate the overall percentage
of individuals who previously had varicella despite a neg-
ative or unclear history, (ii) to assess whether the current
Swiss recommendation age of 40 is reasonable by compar-
ing seropositivity percentages above and below this age,
and (iii) to examine the influence of age, number of sib-
lings, order of siblings, age difference from siblings and
nationality on likelihood of seropositivity. Furthermore, we
examined whether any of these factors could identify po-
tential risk groups amongst individuals with a negative
varicella history and refine the recommendations on testing
for VZV antibodies. In addition (iv), we aimed to compare
the costs of the two approaches recommended by the Swiss
Federal Office of Public Health.
Methods
Study design
This was a retrospective study of the prevalence of serum
varicella IgG in individuals seeking pre-travel advice in the
Travel Clinic of the Epidemiology, Biostatistics and Pre-
vention Institute, University of Zurich, Switzerland. In the
Travel Clinic we advise individuals with a negative or un-
known varicella history (i.e. individuals who do not have
a reliable varicella history) and who have had no previous
varicella vaccination to be tested for varicella antibodies
and we vaccinate those with a negative result. Generally
only individuals aged <40 years are tested in accordance
with Swiss recommendations. However, some individu-
als above this age were also tested upon their request.
Anonymised VZV serology results from December 2008 to
August 2015 were analysed retrospectively. No ethics ap-
proval was necessary for this study as it was a retrospective
analysis of anonymised data.
Available data
The following anonymous data were analysed: age, gender,
year of birth, nationality, number of siblings, year of birth
of siblings, VZV serology results.
Varicella-zoster virus serology
All VZV serology tests were conducted in the laboratory
of the Institute of Virology at the University of Zurich. The
VIDAS bioMérieux VZV IgG, a multiparametric immun-
oassay system for medium throughput, based on enzyme-
linked fluorescent assay (ELFA) technology was used. In
September 2012, the laboratory switched to a new system,
Virion/Serion VZV IgG kit enzyme-linked immunosorbent
assay (ELISA).
Vaccination cost analysis
We compared emerging costs of the two approaches recom-
mended by The Swiss Federal Office of Public Health: (i)
to vaccinate individuals between 11 and <40 years of age
who had not contracted varicella naturally in the past or (ii)
to perform a VZV serology test and vaccinate those with a
negative result.
Statistical analysis
Data were analysed with Stata 13.0 (Stata Corp, Texas).
Univariate and bivariate analyses were performed. Differ-
ences in proportions were assessed using a χ2 test or Fish-
er’s exact test, where applicable. A test for trend was ap-
plied for ordered categorical variables. For continuous vari-
ables with a non-normal distribution the median was re-
ported. A logistic regression was performed to adjust for
potential confounders. All variables that were considered to
be possibly associated with the result of the VZV IgG test
result were included in the logistic regression model.
Results
Demographics
Overall, the sera of 1757 individuals with a negative or un-
known varicella history were tested for VZV antibodies.
Figure 1
Seronegativity for varicella according to age group in travellers
seeking pre-travel advice at the Travel Clinic of the University of
Zurich between December 2008 and August 2015 who had an
uncertain or negative varicella history (n = 1749).
Figure 2
Varicella seropositivity according to nationality in travellers seeking
pre-travel advice at the Travel Clinic of the University of Zurich
between December 2008 and August 2015 who had an uncertain
or negative varicella history (n = 1749).
SC = South Central; SE = South-East; E = East; Europe =
European countries except Switzerland; χ2 test p <0.001
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Out of these, 860 (49.0%) were male and the median age
was 31.6 years (range 11–72 years).
In 1560 individuals (88.8%) the nationality was known;
1270 (81.5%) were Swiss, 219 (14.0%) from other
European countries, 27 (1.7%) from South Central, Eastern
or South-Eastern Asia, 8 (0.5%) from Western Asia, 18
(1.2%) from the Americas and 17 (1.1%) from Africa.
In 1474 individuals (83.9%), the number of siblings was
known; 322 (22.0%) had no sibling, 622 (42.4%) had one
sibling, 331 (22.6%) had two siblings, 130 (8.9%) had three
siblings and 61 (4.1%) at least four. Out of all travellers
with siblings, 393 (35.6%) were first-born, 487 (44.1%)
second, 147 (13.3%) third and 78 (7.1%) were born in the
fourth or a later position.
Univariate analysis
Out of all tested individuals, 1593 (90.7%) had a positive,
156 (8.9%) a negative and 8 (0.4%) an inconclusive result.
Individuals with inconclusive results were not included in
the further analysis.
We found a decreasing trend for varicella seronegativity
with increasing age (p = 0.008, fig. 1). Those aged less than
40 years were significantly more often seronegative (137/
1435, 9.5%) than those aged 40 years and above (19/314,
6.0%, p = 0.049). Overall, slightly more males were sero-
positive than females (92.7% vs 89.6%, p = 0.024).
Individuals from Africa had the highest percentage of sero-
positivity (16/17, 94.1%) followed by persons of Swiss na-
tionality (1166/1270, 92.0%). Seropositivity of individuals
from other European countries, the Americas or Western
Asia ranged between 83% and 88%, and persons from
South Central, South-Eastern or Eastern Asia had the low-
est seropositivity (65.4%, fig. 2). Seroprevalence varied
between European countries; for example, VZV sero-
prevalence was 91% (107/118) in travellers from Germany,
91% in those from Spain (10/11), 71% in individuals from
France (5/7), and 100% in travellers from the UK (5/5) or
Austria (8/8).
The percentage of seropositivity increased considerably
with number of siblings. Whereas 85.4% of persons
without siblings had a positive varicella titre, 95.1% of
those with at least four siblings were seropositive (p
<0.001, table 1).
We found a trend for increasing seropositivity with declin-
ing age difference between siblings. This trend was ob-
served in those with older siblings as well as in those with
younger siblings (table 2). However, the differences were
not statistically significant.
We did not find that the position within family birth order
was associated with varicella seropositivity (data not
shown).
Multivariate analysis
After gender, number of siblings, order within siblings and
nationality were taken into account, age was significantly
associated with a positive varicella titre. With every
10-year increase the odds of a positive varicella titre rose
by 1.37 (95% confidence interval [CI] 1.09–1.76, p =
0.007, table 3). The number of siblings was also signific-
antly associated with varicella seropositivity after adjusting
for gender, age, order within siblings and nationality (odds
ratio [OR] 1.34, 95% CI 0.98–1.82, p = 0.065).
Individuals from other European countries (except Switzer-
land) and persons from South Central / South-Eastern /
Eastern Asia had a significantly lower prevalence of sero-
positivity compared with Swiss citizens, even after taking
gender, age, order within siblings and number of siblings
into account (Europe: OR 0.59, 95% CI 0.36–0.95, p = 0.03
and South Central / South-Eastern / Eastern Asia: OR 0.16,
95% CI 0.06–0.41, p <0.001).
Vaccination costs
In Switzerland, two varicella doses cost around 170 Swiss
francs including all charges while the expenses for varicella
serology are around 65 Swiss francs. For the individuals
tested in this study, costs for varicella serology plus vac-
cination of those with a negative result added up to some
141 000 Swiss francs. If all persons had received two vac-
cine doses without previous testing, costs would have ad-
ded up to approximately 298 500 Swiss francs.
Discussion
In the current study, more than 90% of individuals, aged
11 to 72 years, with an unknown or negative varicella his-
tory were seropositive for VZV antibodies. Seropositivity
increased with age and number of siblings, whereas the age
difference between siblings and the order of birth did not
significantly influence a person’s varicella serostatus. In
all individuals from Switzerland and Africa seroprevalen-
ce was higher than 90%. In those persons originating from
other countries in Europe or Western Asia seroprevalen-
ce ranged between 85 and 90%, while seroprevalence was
only 83% in individuals from the Americas and 65% in in-
dividuals from South Central, South-East and East Asia.
However, the numbers of travellers originating from coun-
tries other than Switzerland were small. Thus seroprevalen-
ce data in these groups should be interpreted with caution.
Table 1: Results of varicella serology according to number of siblings in travellers seeking pre-travel advice at the Travel Clinic of the University of Zurich between
December 2008 and August 2015 who had an uncertain or negative varicella history (n = 1757).
Varicella serologyNumber of siblings
Negative n (%) Positive n (%)
0 47 (14.6) 275 (85.4)
1 56 (9.0) 566 (91.0)
2 19 (5.7) 312 (94.3)
3 9 (6.9) 121 (93.1)
≥4 3 (4.9) 58 (95.1)
Test for trend p <0.001
Original article Swiss Med Wkly. 2016;146:w14342
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 6
Age, number of siblings and nationality (origin) have pre-
viously been shown to be associated with VZV serostatus
in children and adolescents [1, 2]. Heininger et al. demon-
strated a positive correlation between presence of VZV
antibodies and the number of siblings living in the same
household (90.1% occurrence of antibodies in people with
no siblings and more than 96% seroprevalence in people
with one or more siblings). Similar results were observed
in a study conducted by Jerant et al. in young US-military
soldiers [13]. Seroprevalence to varicella is generally lower
in tropical countries [17, 18] and thus the finding of 65%
seronegatives in those from large parts of Asia is not sur-
prising.
Between 1999 and 2000, the reliability of varicella history
was investigated among children and adolescents aged 1 to
18 years who were hospitalised at the University Children's
Hospital of Basel, Switzerland [5]. Among those with a
positive varicella history, serum samples tested positive in
98%. In those who reported no or a possible previous vari-
cella history, 15.7% (31/197) tested positive. When look-
ing at age groups, a different picture was observed: 3% of
those aged 1 to 4 years, 23% of those aged 5 to 8 years and
74% of older children (aged 9–18 years) tested positive for
varicella despite a negative history. In our study, we report
varicella titres in persons aged 11 years and older. In those
aged 10 to 19 years, we found a varicella positivity of 85%
with an increasing trend in higher age groups. Thus, our
findings are in line with the results from the study conduc-
ted between 1999 and 2000.
We showed that the strategy of applying two vaccine doses
to all individuals with an unknown or negative varicella
history would have been twice as costly as the approach of
performing a serology test and vaccinating only those with
a negative result.
Limitations
Underlying conditions, including immunocompromising
conditions, were not recorded and could not be assessed
in our study sample. Antibody memory towards varicella
has been shown to be impaired in immunocompromised
persons [19]. Furthermore, the sample sizes for individuals
aged 40 years and above, as well as for individuals from re-
gions outside Switzerland, were low, thus our sample may
not be representative for these groups. In addition, we have
information only on the nationality of individuals, but not
on the country where they grew up in.
We tested for VZV antibodies in every traveller with a neg-
ative or unknown varicella history who wished and agreed
to be tested. It is possible that results would have been dif-
ferent in those who did not agree to be tested. Unfortu-
nately, because of data limitations we could not assess how
many individuals reported a positive varicella history or
how many travellers with a negative or unknown varicella
history did not agree to be tested. All travellers receive a
written report on their serology results 10 to 14 days after
testing. Those with a negative VZV serology receive the
recommendation to be vaccinated twice. However, owing
to the anonymous nature of the data we could not check
whether these individuals actually followed our recom-
mendation. In a worst-case scenario, none of those with a
VZV-negative test result received the vaccinations and we
may have missed vaccinating 156 travellers with no protec-
tion against varicella.
Conclusion
From our results it is questionable whether the age of 40 is
a reasonable threshold for performing VZV serology in in-
dividuals with an unknown or negative varicella history in
Switzerland, as 6.0% of tested individuals above the age of
40 were still VZV negative. In age groups above 40, test-
ing for VZV antibodies may be reasonable, especially in
those with no or a small number of siblings as well as in
those originating from the Americas or from South Central,
South-East and East Asia.
Furthermore, our study shows how important pre-travel ad-
vice is in updating vaccination and immunity status.
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Table 2: Does age difference between siblings influence varicella seropositivity in travellers seeking pre-travel advice at the Travel Clinic of the University of Zurich
between December 2008 and August 2015 who had an uncertain or negative varicella history (n = 1757)?
Varicella serologyAge difference
Negative n (%) Positive n (%)
(a) Smallest age difference from older siblings
<2 years 12 (5.3) 213 (94.7)
2 to <4 years 22 (8.7) 232 (91.3)
4 to <6 years 11 (8.4) 120 (91.6)
≥6 years 11 (10.1) 98 (89.1)
Test for trend: p = 0.128
(b) Smallest age difference from younger siblings
<2 years 9 (6.9) 122 (93.1)
2 to <4 years 10 (4.6) 210 (95.5)
4 to <6 years 9 (7.8) 106 (92.2)
6 to <8 years 4 (12.9) 27 (87.1)
≥8 years 4 (10.3) 35 (89.7)
Test for trend: p = 0.163
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Figures (large format)
Figure 1
Seronegativity for varicella according to age group in travellers seeking pre-travel advice at the Travel Clinic of the University of Zurich between
December 2008 and August 2015 who had an uncertain or negative varicella history (n = 1749).
Figure 2
Varicella seropositivity according to nationality in travellers seeking pre-travel advice at the Travel Clinic of the University of Zurich between
December 2008 and August 2015 who had an uncertain or negative varicella history (n = 1749).
SC = South Central; SE = South-East; E = East; Europe = European countries except Switzerland; χ2 test p <0.001
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